What Is the First-Line Treatment for Acromegaly?
This page summarises the primary evidence-based clinical approach for acromegaly and the biochemical targets that define successful treatment. The full structured protocol is one click away.
Primary Treatment Approach
For most patients with acromegaly, a specific surgical intervention is the recommended first-line treatment. The preferred operative route and technique are clearly defined in current clinical guidance — however, the complete algorithm, operative decision criteria, and stepwise approach are available only in the full structured protocol below.
Remission & Control Targets
Treatment response is formally assessed at 12 weeks after the intervention, using two biochemical markers:
- Normalized serum IGF-1
- Random serum GH < 1 µg/L — indicating control and normalization of mortality risk; a level < 0.14 µg/L suggests surgical remission
References
DOI: 10.1210/jc.2014-2700
- We recommend transsphenoidal surgery as the primary therapy in most patients.
- The favored surgical approach is via the transsphenoidal route, using either the operating microscope or the operating endoscope, along with microsurgical technique.
- A serum GH < 0.14 µg/L suggests “surgical remission,” and a level < 1 µg/L indicates “control” and normalization of the mortality risk.
- IGF-1 levels measured at 12 weeks after surgery are a valid reflection of surgical remission.